Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lifts target for Babcock, sees further upside to forecasts

(Sharecast News) - Berenberg has hiked its target price for Babcock from 1,360p to 1,440p and reiterated a 'buy' rating on the stock after raising estimates for the defence engineering business after this week's positive AGM update. Reporting on trading over the first five months of the financial year, Babcock said on Thursday that the strong momentum in the Nuclear division was continued - the unit delivered double-digit revenue growth over the past three years - driven by both civil nuclear and submarine activity.

"This bodes well for profitability, as Nuclear is the highest margin division, in our view," Berenberg said.

Meanwhile, the company has secured several contract wins and additional strategic partnerships during the period, the broker highlighted.

"We continue to view the company's medium-term group mid-single-digit revenue growth guidance as conservative, set against the GBP16bn shipbuilding pipeline and a multitude of partnerships formed with other defence companies. We estimate 10% upside to our FY30 revenue estimate from these partnerships alone," Berenberg said.

The broker pointed out that Babcock's peers trade at higher valuation multiples, and shares should re-rate to trade in line with the sector.

The stock was 1./4% higher at 1,251.65p by 1144 BST, having gained 23% over the past month.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.